Category: Intellectual property
-
Pharma Licenses University Antibiotic Enhancements
5 August 2015. Technologies that remove side-effect causing toxicity from gentamicin, a powerful antibiotic drug, are being licensed from two universities by La Jolla Pharmaceutical Company. Financial terms of the agreements between the San Diego biopharmaceutical developer and University of Alabama in Birmingham and University of Indiana were not disclosed. Gentamicin is one of a…
-
Crop Biotech Acquires Genomic Engineering Technology
29 July 2015. Calyxt Inc., a biotechnology company developing new varieties of food crops, is licensing technology from University of Minnesota for more efficient modification of plant genomes. Financial details of the agreement between Calyxt, in New Brighton Minnesota, and the university were not disclosed. Calyxt — until recently known as Cellectis Plant Sciences —…
-
Patent Awarded for Fractal Connections in Implants
28 July 2015. Electronic microcircuits designed to resemble fractals in nature used in implanted medical devices received a patent from the U.S. Patent and Trademark Office. Patent number 9,079,017 was awarded on 14 July 2015 to physicist and materials scientist Richard Taylor at University of Oregon and Simon Brown at University of Canterbury in New…
-
Cancer Specialists Offer Plan to Reduce Drug Prices
23 July 2015. A group of 118 cancer specialists proposed steps to reduce the cost of drugs to cancer patients, calling the current system of drug pricing “unsustainable and not affordable for many patients.” Their recommendations appear today in a commentary published in the journal Mayo Clinic Proceedings. Pharmaceutical industry representatives, however, say drugs play…
-
Cough Diagnostics Mobile App in Clinical Trial
22 July 2015. A smartphone app designed to diagnose the nature of a cough by the sound it makes is now being tested in a clinical trial in Australia. The app, developed in the lab of engineering professor Udantha Abeyratne at University of Queensland in Brisbane, Australia was licensed to a spin-off company from the…
-
Univ. of Arizona Spin-Off Licenses Cancer Therapy
10 July 2015. A new company spun-off from University of Arizona licensed a cancer therapy based on research by a pharmacy faculty member at the school, also the company’s founder. Synactix Pharmaceuticals Inc. in Tucson is founded by pharmacology professor Hong-yu Li and postdoctoral fellow Brendan Fett. Li’s lab at Arizona studies cancer therapeutics, particularly…
-
Patents Awarded to Women Rise, Particularly in Academia
8 July 2015. Patents issued to women are still a minority at the U.S. Patent and Trademark Office, but their percentages increased over the past 4 decades, notably among recipients at academic institutions. A team of information technology and library science researchers from Indiana University, Simmons College in Boston, University of Washington, and Université de…
-
Allergan Acquires Merck Migraine Therapies
8 July 2015. The pharmaceutical company Allergan is licensing therapies for treatment and prevention of migraines being developed by Merck, another pharma company. The agreement is expected to bring Merck $250 million over the next year, as well as undisclosed milestone and royalty payments from Allergan. Migraine is a neurological syndrome causing severe headaches along with…
-
Juno, Celgene Partner in $1 Billion Immunotherapy Deal
30 June 2015. Biotechnology company Juno Therapeutics Inc. and biopharmaceutical developer Celgene Corp. are collaborating on therapies that harness the immune system to treat cancer and autoimmune diseases over the next 10 years. The agreement is expected to bring Juno nearly $1 billion from Celgene in upfront payments and stock purchases. Juno Therapeutics, headquartered in…
-
Allied-Bristol Licenses Chinese Root Extract Technology
22 June 2015. A joint venture of drug maker Bristol-Myers Squibb and science commercialization company Allied Minds is licensing research at Harvard University on the actions of a Chinese root extract with therapeutic potential against fibrosis, inflammation, and autoimmune disorders. Financial aspects of the agreement between Harvard and Allied-Bristol Life Sciences were not disclosed. The…